Endotoxin preconditioning as a model to uncover protective pathways in sepsis-induced renal injury.
内毒素预处理作为模型揭示脓毒症引起的肾损伤的保护途径。
基本信息
- 批准号:9172789
- 负责人:
- 金额:$ 37.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-25 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Renal Failure with Renal Papillary NecrosisAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsCellsChemotactic FactorsDataDiseaseDoseEnd stage renal failureEndotoxinsExposure toFailureFunctional disorderGoalsHealthHumanImmuneImmunosuppressionInfectionInflammatoryInjuryIntensive Care UnitsInvestigationKidneyKnowledgeMediatingMetabolicMetabolismMissionModelingMolecularMorbidity - disease rateOrganOutcomeOxidative StressParticipantPathway interactionsPatient-Focused OutcomesPatientsPhenotypePreventionPrevention approachPropertyPublic HealthPublishingQuality of lifeRenal TissueRenal tubule structureResearchResistanceRoleSepsisSignal TransductionSmall Interfering RNAStagingSubgroupTestingTherapeuticTherapeutic Clinical TrialTherapeutic InterventionTissuesUnited States National Institutes of HealthWorkbaseexpectationfascinatefightinghuman diseaseimprovedin vivointerestmacrophagemetabolic profilemetabolomicsmortalitynoveloutcome forecastpreconditioningpreventresponsetargeted treatmenttranscriptomics
项目摘要
Gram-negative sepsis remains a major cause of mortality and morbidity in hospitalized patients,
especially when complicated by acute kidney injury (AKI). The pathophysiology of AKI in sepsis continues
to be poorly understood resulting in the persistent failure of clinical therapeutic trials. Recently, we
identified a novel pathway of renal injury in sepsis involving direct interactions between filtered
endotoxin and S1 proximal tubules. This endotoxin-S1 interaction resulted in severe peroxisomal damage
and oxidative stress in downstream S2 and S3 segments. Remarkably, this pathway of injury had no
requirement for competent immune cells. In this proposal, we continue our investigation of sepsis and
AKI by examining the mechanisms of renal endotoxin preconditioning. The phenomenon of protective
preconditioning is unique in that it represents a state of resistance to the deleterious effects of
endotoxin and yet, a preserved ability to effectively contain and eliminate infections. Unraveling the
pathways involved in endotoxin tolerance has great potential for identifying potential targets that can be
used for the prevention and treatment of human sepsis. Historically, preconditioning has been
investigated in immune cells and their isolated responses to repeated endotoxin exposure. Little is
known about the mechanisms leading to tissue protection in whole organs such as the kidney. Based on
strong preliminary data, the central hypothesis of this proposal is that macrophages are essential
components of the protective pathways of preconditioning. This is a novel hypothesis because it depicts
the macrophage as an active and beneficial participant in the tolerant phenotype. In specific aim 1, we
will establish the essential role of macrophages and examine their cross-talk with renal tubules such as
the S1 segment. In specific aim 2, we will determine the metabolic and transcriptomic changes imparted
by protective macrophages on S1 tubules. We will also identify key metabolites that can be used directlt
to treat sepsis. In specific aim 3, we will examine the potential of protective macrophages to treat
sepsis in a cell transfer approach. We believe that the proposed studies, by increasing our understanding
of endotoxin preconditioning, have great translational potential and will uncover a novel and global
approach to the prevention and treatment of sepsis and sepsis-induced AKI.
革兰氏阴性脓毒症仍然是住院患者死亡和发病的主要原因,
尤其是当并发急性肾损伤(阿基)时。脓毒症中阿基的病理生理学继续
对这些问题的认识不足,导致临床治疗试验的持续失败。最近我们
发现了一种新的脓毒症肾损伤途径,
内毒素和S1近端小管。这种内毒素-S1相互作用导致严重的过氧化物酶体损伤
以及下游S2和S3节段中的氧化应激。值得注意的是,这种损伤途径没有
需要有能力的免疫细胞在这个建议中,我们继续我们的调查败血症,
内毒素预处理对急性肾损伤的保护作用。保护现象
预处理是独特的,因为它代表了一种抵抗有害影响的状态,
内毒素,但保留了有效控制和消除感染的能力。Unraveling the
参与内毒素耐受性的途径具有很大的潜力,用于鉴定可以
用于预防和治疗人败血症。从历史上看,预处理一直是
研究免疫细胞及其对重复内毒素暴露的孤立反应。之甚少
目前还不清楚导致整个器官(如肾脏)组织保护的机制。基于
强有力的初步数据,这一建议的中心假设是,巨噬细胞是必不可少的
预处理的保护途径的组成部分。这是一个新颖的假设,因为它描述了
巨噬细胞作为耐受表型的积极和有益的参与者。在具体目标1中,我们
将建立巨噬细胞的基本作用,并检查它们与肾小管的相互作用,
S1段。在具体的目标2中,我们将确定代谢和转录组学的变化,
由S1小管上的保护性巨噬细胞产生我们还将确定可直接用于治疗的关键代谢物。
来治疗败血症在具体目标3中,我们将研究保护性巨噬细胞治疗
脓毒症的细胞转移方法。我们认为,通过增加我们的了解,
内毒素预处理,具有很大的翻译潜力,将揭示一个新的和全球性的
预防和治疗脓毒症和脓毒症诱导的阿基的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pierre C Dagher其他文献
Renal Toll-like receptors: recent advances and implications for disease
肾 Toll 样受体:最新进展及其对疾病的影响
- DOI:
10.1038/ncpneph0300 - 发表时间:
2006-10-01 - 期刊:
- 影响因子:39.800
- 作者:
Tarek M El-Achkar;Pierre C Dagher - 通讯作者:
Pierre C Dagher
Pierre C Dagher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pierre C Dagher', 18)}}的其他基金
Indiana Center for Advanced Renal Microscopy and Molecular Imaging
印第安纳高级肾脏显微镜和分子成像中心
- 批准号:
10747616 - 财政年份:2023
- 资助金额:
$ 37.15万 - 项目类别:
Protective pathways in sepsis-induced renal injury
脓毒症引起的肾损伤的保护途径
- 批准号:
9318114 - 财政年份:2016
- 资助金额:
$ 37.15万 - 项目类别:
Endotoxin preconditioning as a model to uncover protective pathways in sepsis-induced renal injury
内毒素预处理作为模型揭示脓毒症引起的肾损伤的保护途径
- 批准号:
10444008 - 财政年份:2016
- 资助金额:
$ 37.15万 - 项目类别:
Endotoxin preconditioning as a model to uncover protective pathways in sepsis-induced renal injury
内毒素预处理作为模型揭示脓毒症引起的肾损伤的保护途径
- 批准号:
10653145 - 财政年份:2016
- 资助金额:
$ 37.15万 - 项目类别:
Endotoxin preconditioning as a model to uncover protective pathways in sepsis-induced renal injury.
内毒素预处理作为模型揭示脓毒症引起的肾损伤的保护途径。
- 批准号:
9765302 - 财政年份:2016
- 资助金额:
$ 37.15万 - 项目类别:
Modifying kidney injury through p53 signaling.
通过 p53 信号传导改变肾损伤。
- 批准号:
8696136 - 财政年份:2014
- 资助金额:
$ 37.15万 - 项目类别:
Pathophysiology of sepsis-induced renal injury
脓毒症引起的肾损伤的病理生理学
- 批准号:
7842471 - 财政年份:2009
- 资助金额:
$ 37.15万 - 项目类别:
Pathophysiology of sepsis-induced renal injury
脓毒症引起的肾损伤的病理生理学
- 批准号:
7652910 - 财政年份:2009
- 资助金额:
$ 37.15万 - 项目类别:
Pathophysiology of sepsis-induced renal injury
脓毒症引起的肾损伤的病理生理学
- 批准号:
8450638 - 财政年份:2009
- 资助金额:
$ 37.15万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 37.15万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 37.15万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 37.15万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 37.15万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 37.15万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 37.15万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 37.15万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 37.15万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 37.15万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 37.15万 - 项目类别: